Liquidia Stock Gets Stronger EPS Estimate from HC Wainwright

Key Points

• HC Wainwright raised Liquidia’s FY2028 EPS estimate to $4.94 from $4.49 and maintained a “Buy” rating with a $65 price target. It also forecast EPS of $5.61 for FY2029 and $6.36 for FY2030.
• Analyst sentiment is mixed: BTIG upgraded Liquidia to “Buy,” while Wall Street Zen downgraded it to “Hold.” Overall, the stock carries an average “Hold” rating and an average price target of $72.85.
• Liquidia’s latest quarterly revenue surged 1,842.1% year over year to $171.68 million, though EPS of $0.74 narrowly missed the $0.76 consensus estimate. Insiders sold 741,598 shares worth about $40.8 million over the prior 90 days.

Liquidia Corporation (NASDAQ:LQDA - Free Report) - Research analysts at HC Wainwright increased their FY2028 earnings per share estimates for shares of Liquidia in a research report issued to clients and investors on Thursday, October 15th. HC Wainwright analyst A. Fein now expects that the company will post earnings of $4.94 per share for the year, up from their previous forecast of $4.49. HC Wainwright has a "Buy" rating and a $65.00 price target on the stock. The consensus estimate for Liquidia's current full-year earnings is $2.05 per share. HC Wainwright also issued estimates for Liquidia's FY2029 earnings at $5.61 EPS and FY2030 earnings at $6.36 EPS.

LQDA has been the subject of a number of other research reports. Wall Street Zen cut shares of Liquidia from a "buy" rating to a "hold" rating in a research note on Saturday, October 3rd. Royal Bank Of Canada set a $65.00 price target on Liquidia in a research report on Thursday. Weiss Ratings upgraded Liquidia from a "sell (d-)" rating to a "hold (c)" rating in a research report on Tuesday, September 22nd. BTIG Research raised Liquidia from a "neutral" rating to a "buy" rating and set a $70.00 price target for the company in a report on Wednesday, October 14th. Finally, Stephens set a $130.00 price objective on Liquidia in a research report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $72.85.

Liquidia Stock Performance

Shares of Liquidia stock opened at $34.35 on Monday. Liquidia has a 12-month low of $21.94 and a 12-month high of $93.61. The stock has a market capitalization of $3.07 billion, a P/E ratio of 25.07, a price-to-earnings-growth ratio of 0.30 and a beta of 0.61. The company has a 50-day simple moving average of $60.09 and a 200 day simple moving average of $61.73. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The company had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. During the same quarter in the prior year, the company earned ($0.49) earnings per share. The business's revenue was up 1842.1% compared to the same quarter last year.

Insider Transactions at Liquidia

In other Liquidia news, Director Katherine Rielly-Gauvin sold 36,789 shares of the company's stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $74.99, for a total transaction of $2,758,807.11. Following the transaction, the director owned 44,637 shares of the company's stock, valued at approximately $3,347,328.63. This represents a 45.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Roger Jeffs sold 32,744 shares of the stock in a transaction on Monday, October 12th. The shares were sold at an average price of $28.48, for a total value of $932,549.12. Following the completion of the transaction, the chief executive officer owned 1,125,848 shares in the company, valued at $32,064,151.04. The trade was a 2.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 741,598 shares of company stock worth $40,795,640 over the last ninety days. 25.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Liquidia

Several large investors have recently made changes to their positions in the company. Globeflex Capital L P acquired a new position in Liquidia during the 2nd quarter valued at about $175,000. Nykredit A S acquired a new stake in shares of Liquidia during the 2nd quarter worth approximately $177,000. Apollon Wealth Management LLC acquired a new stake in shares of Liquidia during the 1st quarter worth approximately $247,000. Archer Investment Corp acquired a new stake in shares of Liquidia during the 1st quarter worth approximately $259,000. Finally, Fluent Financial LLC bought a new stake in shares of Liquidia during the second quarter worth approximately $287,000. Institutional investors and hedge funds own 64.54% of the company's stock.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia’s settlement with United Therapeutics resolves the litigation surrounding YUTREPIA, removing a major legal overhang and improving visibility for the product’s commercialization. The stock recently rallied sharply on the news, though the agreement is described as costly. Why Liquidia Is Up After YUTREPIA Litigation Settlement
• Positive Sentiment: LifeSci Capital upgraded Liquidia to “Outperform” from “Market Perform,” reflecting increased confidence following the litigation resolution. LifeSci Capital Upgrades Liquidia
• Positive Sentiment: BTIG Research raised Liquidia to “Buy,” adding to the bullish analyst commentary. HC Wainwright also maintained a “Buy” rating and lifted its price target to $65 from $58, implying substantial upside from recent trading levels.
• Neutral Sentiment: Trading volume became unusually high after the analyst upgrades, indicating strong investor attention and repositioning following the settlement and rating changes. Liquidia Sees Unusually High Trading Volume
• Negative Sentiment: Needham & Company reduced its price target for Liquidia, signaling that some analysts believe the stock’s valuation or the financial impact of the settlement warrants a more cautious outlook. Liquidia Price Target Cut by Needham

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia's lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.